NO802683L - Fremgangsmaate for fremstilling av polypeptidet psp - Google Patents

Fremgangsmaate for fremstilling av polypeptidet psp

Info

Publication number: NO802683L
Authority: NO; Norway
Prior art keywords: psp; cys; polypeptide; asx; pro
Prior art date: 1979-09-11

Application number

NO802683A

Other languages

English (en)

Norwegian (no)

Inventor

Klavs Holger Joergensen

Karin Damm Joergensen

Lars Thim

Original Assignee

Novo Industri As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-09-11

Filing date

1980-09-10

Publication date

1981-05-07

1980-09-10 Application filed by Novo Industri As filed Critical Novo Industri As

1981-05-07 Publication of NO802683L publication Critical patent/NO802683L/no

Links

238000000034 method Methods 0.000 title claims description 24
229920001184 polypeptide Polymers 0.000 title claims description 22
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 21
108090000765 processed proteins & peptides Proteins 0.000 claims description 21
102000004196 processed proteins & peptides Human genes 0.000 claims description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
102000004169 proteins and genes Human genes 0.000 claims description 17
108090000623 proteins and genes Proteins 0.000 claims description 17
102000004877 Insulin Human genes 0.000 claims description 11
108090001061 Insulin Proteins 0.000 claims description 11
239000000284 extract Substances 0.000 claims description 11
229940125396 insulin Drugs 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
210000004907 gland Anatomy 0.000 claims description 10
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 9
239000000812 cholinergic antagonist Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 3
238000001704 evaporation Methods 0.000 claims description 3
238000011084 recovery Methods 0.000 claims description 3
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 2
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 2
230000008020 evaporation Effects 0.000 claims description 2
238000000926 separation method Methods 0.000 claims description 2
238000000605 extraction Methods 0.000 claims 2
238000011097 chromatography purification Methods 0.000 claims 1
229940039227 diagnostic agent Drugs 0.000 claims 1
239000000032 diagnostic agent Substances 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
239000013049 sediment Substances 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
239000000243 solution Substances 0.000 description 27
238000005119 centrifugation Methods 0.000 description 21
230000000694 effects Effects 0.000 description 21
239000002244 precipitate Substances 0.000 description 19
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
239000006228 supernatant Substances 0.000 description 11
102000051325 Glucagon Human genes 0.000 description 9
108060003199 Glucagon Proteins 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000003480 eluent Substances 0.000 description 9
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 9
229960004666 glucagon Drugs 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
229920005654 Sephadex Polymers 0.000 description 6
239000012507 Sephadex™ Substances 0.000 description 6
238000005571 anion exchange chromatography Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
238000005277 cation exchange chromatography Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000001155 isoelectric focusing Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000012588 trypsin Substances 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
108090000919 Pyroglutamyl-Peptidase I Proteins 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000001450 anions Chemical class 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000010828 elution Methods 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
210000002460 smooth muscle Anatomy 0.000 description 4
238000003756 stirring Methods 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241000282887 Suidae Species 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000001839 endoscopy Methods 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000012452 mother liquor Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
230000002040 relaxant effect Effects 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
241000700198 Cavia Species 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
108010019160 Pancreatin Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
230000001078 anti-cholinergic effect Effects 0.000 description 2
230000002921 anti-spasmodic effect Effects 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
230000006240 deamidation Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000005176 gastrointestinal motility Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000008991 intestinal motility Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000004130 lipolysis Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000004899 motility Effects 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
229940055695 pancreatin Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
229960001999 phentolamine Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000003531 protein hydrolysate Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000005185 salting out Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
230000002048 spasmolytic effect Effects 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
102000045576 Lactoperoxidases Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
-1 PSP compound Chemical class 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
108010027597 alpha-chymotrypsin Proteins 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000035873 hypermotility Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
108010056579 pancreatic spasmolytic polypeptide Proteins 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Reinforced Plastic Materials (AREA)

NO802683A 1979-09-11 1980-09-10 Fremgangsmaate for fremstilling av polypeptidet psp NO802683L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB7931518		1979-09-11

Publications (1)

Publication Number	Publication Date
NO802683L true NO802683L (no)	1981-05-07

Family

ID=10507754

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO802683A NO802683L (no)	1979-09-11	1980-09-10	Fremgangsmaate for fremstilling av polypeptidet psp

Country Status (15)

Country	Link
JP (1)	JPS609760B2 (sv)
AT (1)	AT373149B (sv)
AU (1)	AU537523B2 (sv)
BE (1)	BE885199A (sv)
CA (1)	CA1160624A (sv)
CH (1)	CH646414A5 (sv)
DE (1)	DE3034198A1 (sv)
DK (1)	DK380880A (sv)
ES (1)	ES494917A0 (sv)
FI (1)	FI802828A (sv)
FR (1)	FR2464942A1 (sv)
IT (1)	IT1195032B (sv)
NL (1)	NL8005084A (sv)
NO (1)	NO802683L (sv)
SE (1)	SE8006333L (sv)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB924815A (en) *	1959-12-24	1963-05-01	Maurice Roux	Improvements in methods of preparation of polypeptides of spasmolytic activity

1980
- 1980-09-08 DK DK380880A patent/DK380880A/da not_active Application Discontinuation
- 1980-09-09 NL NL8005084A patent/NL8005084A/nl not_active Application Discontinuation
- 1980-09-10 NO NO802683A patent/NO802683L/no unknown
- 1980-09-10 FR FR8019545A patent/FR2464942A1/fr active Granted
- 1980-09-10 SE SE8006333A patent/SE8006333L/sv not_active Application Discontinuation
- 1980-09-10 AT AT0455180A patent/AT373149B/de not_active IP Right Cessation
- 1980-09-10 ES ES494917A patent/ES494917A0/es active Granted
- 1980-09-10 FI FI802828A patent/FI802828A/fi not_active Application Discontinuation
- 1980-09-10 CH CH681480A patent/CH646414A5/de not_active IP Right Cessation
- 1980-09-11 BE BE6/47265A patent/BE885199A/fr not_active IP Right Cessation
- 1980-09-11 DE DE19803034198 patent/DE3034198A1/de not_active Withdrawn
- 1980-09-11 CA CA000360561A patent/CA1160624A/en not_active Expired
- 1980-09-11 JP JP55125375A patent/JPS609760B2/ja not_active Expired
- 1980-09-11 AU AU62317/80A patent/AU537523B2/en not_active Ceased
- 1980-09-11 IT IT24588/80A patent/IT1195032B/it active

Also Published As

Publication number	Publication date
SE8006333L (sv)	1981-03-12
JPS609760B2 (ja)	1985-03-12
JPS56123996A (en)	1981-09-29
IT1195032B (it)	1988-09-28
DE3034198A1 (de)	1981-04-09
FR2464942B1 (sv)	1984-10-26
AU6231780A (en)	1981-03-19
ATA455180A (de)	1983-05-15
NL8005084A (nl)	1981-03-13
FI802828A (fi)	1981-03-12
CH646414A5 (en)	1984-11-30
ES8105699A1 (es)	1981-06-16
ES494917A0 (es)	1981-06-16
CA1160624A (en)	1984-01-17
AU537523B2 (en)	1984-06-28
FR2464942A1 (fr)	1981-03-20
DK380880A (da)	1981-05-12
BE885199A (fr)	1981-03-11
IT8024588A0 (it)	1980-09-11
AT373149B (de)	1983-12-27

Publication	Publication Date	Title
US4370317A (en)	1983-01-25	Pancreatic spasmolytic polypeptide
EP0309100B1 (en)	1997-07-23	Use of amylin or CGRP for the treatment of diabetes mellitus
CN102643339B (zh)	2014-04-09	一种glp-1类似物、制备方法及其应用
WO2021204170A1 (zh)	2021-10-14	一种中华冀土鳖虫来源的具有降血脂功能的活性肽及其制备方法和应用
AU2016324119B2 (en)	2019-11-14	Long-acting adrenomedullin derivative
WO1988007863A1 (en)	1988-10-20	Human somatomedin carrier protein subunits and process for producing them
US6468536B1 (en)	2002-10-22	Use of proteins as anti-diabetes agents
CN111939179B (zh)	2022-08-19	眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用
US5288708A (en)	1994-02-22	Pharmacologically active substance BPC, the process for its preparation and its use in the therapy
JPS61500119A (ja)	1986-01-23	ひとカルシトニン遺伝子関連ペプチド
NO802683L (no)	1981-05-07	Fremgangsmaate for fremstilling av polypeptidet psp
US4806336A (en)	1989-02-21	Human intestinal hormone and its use
CN112125952B (zh)	2021-11-30	一种猪源ace抑制活性多肽与药物组合物或食品及应用
CN111303298B (zh)	2023-03-21	含有磷酸酶的融合蛋白及其产品和应用
GB2059970A (en)	1981-04-29	Spasmolytic polypeptide
CN107365375B (zh)	2019-03-01	一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
IE50966B1 (en)	1986-08-20	Spasmolytic polypeptide
WO1992004368A1 (en)	1992-03-19	Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
WO2014121492A1 (zh)	2014-08-14	Sp肽或其衍生物在制备降低il-13水平的药物中的应用
US4840785A (en)	1989-06-20	Mammal intestinal hormone precursor and its use
WO1993018065A1 (en)	1993-09-16	Physiologically active proteinaceous substance
JPH07119234B2 (ja)	1995-12-20	トリペプチド
LU83206A1 (de)	1981-06-24	Gereinigtes polypeptid,verfahren zum isolieren und verwendung desselben sowie pharmazeutische zusammensetzung und waessrige sterile loesung
JPH03220131A (ja)	1991-09-27	カソキシンｃを有効成分とする血圧降下剤
US20140235545A1 (en)	2014-08-21	The use of HCV immunogenic peptide or a derivative thereof in the prevention or treatment of arthritis